ABIOMED

Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

Revenue(FY, 2018)

$593.7 M

Market capitalization(2018-06-22)

$19 B

Type

Public

Danvers, US

Size (employees)

908 (est)

Website

abiomed.com

ABIOMED is headquartered in Danvers, US

Report incorrect company information

ABIOMED Office Locations

ABIOMED has offices in Danvers and Aachen

Danvers, US (HQ)

22 Cherry Hill Dr

Aachen, DE

3 Neuenhofer Weg

Show all (2)

Report incorrect company information

ABIOMED Financials and Metrics

ABIOMED Financials

ABIOMED's revenue was reported to be $593.75 m in FY, 2018

Summary

USD
Revenue (FY, 2018)	593.7 m
Gross profit (FY, 2018)	495.2 m
Gross profit margin (FY, 2018), %	83.4%
Net income (FY, 2018)	112.2 m
EBIT (FY, 2018)	157.1 m
Market capitalization (22-Jun-2018)	19 b
Closing share price (22-Jun-2018)	427.3
Cash (31-Mar-2018)	43 m

ABIOMED's current market capitalization is $19 b.

Income Statement

Annual

USD	FY, 2014	FY, 2015	Y, 2016	FY, 2017	FY, 2018
Revenue	183.6 m	230.3 m	329.5 m	445.3 m	593.7 m
Revenue growth, %		25%	43%	35%
Cost of goods sold					98.6 m
Gross profit					495.2 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Revenue	44.3 m	46.2 m	48.8 m	51.9 m	62 m	73.4 m	76.4 m	85.8 m	103 m	103 m	114.7 m	132.5 m	132.8 m
General and administrative expense	26.2 m	24.4 m	31.6 m	29.5 m	30.1 m	37.3 m	39.8 m	41.9 m	51 m	53.1 m	53.9 m	60.6 m	60.1 m
R&D expense	7.7 m	7.8 m	9.1 m	8.7 m	8.4 m	10.2 m	11.6 m	13.8 m	15.7 m	18.1 m	16.3 m	16.9 m	19.4 m
Operating expense total	42.9 m	41.6 m	50.3 m	47.8 m	48.3 m	58.4 m	63.5 m	68.4 m	81.8 m	88.4 m	89.3 m	99.4 m	101.1 m

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018
Cash	20.9 m	22.4 m	48.2 m	39 m	43 m
Accounts Receivable	24.4 m	31.8 m	42.8 m	54.1 m	70 m
Inventories	13.9 m	16.8 m	26.7 m	34.9 m	50.2 m
Current Assets	118 m	220.1 m	288.4 m	327 m	494.3 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Cash	10.1 m	22.6 m	34.7 m	17.5 m	19.5 m	40.4 m	54.4 m	53.2 m	38.3 m	54.7 m	61.1 m	44 m	44.5 m
Accounts Receivable	21.1 m	23 m	22.8 m	23.1 m	28.4 m	34.4 m	37.1 m	36.8 m	41.3 m	46.6 m	50.2 m	53.6 m	57.3 m
Inventories	15.6 m	14.8 m	13.9 m	13.4 m	15.4 m	21.2 m	23 m	25.5 m	29.1 m	31.5 m	32.1 m	36.9 m	40.6 m
Current Assets	110.6 m	119.7 m	127.2 m	135.3 m	160.6 m	244.1 m	265.4 m	281.7 m	300.3 m	319.9 m	333.4 m	350.9 m	370.2 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018
Net Income	7.4 m	113.7 m	38.1 m	52.1 m	112.2 m
Depreciation and Amortization		2.8 m	3.3 m	6.2 m	11 m
Inventories	(622 k)	(7 m)	(11 m)	(12.3 m)	(15.7 m)
Accounts Payable	(54 k)	3.4 m	(2.6 m)	7.6 m	4.4 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Net Income	(664 k)	3.7 m	(1.7 m)	3.8 m	12.7 m	8.9 m	7.7 m	10.6 m	12.9 m	8.9 m	15.4 m
Depreciation and Amortization	1.3 m	1.9 m
Inventories	(876 k)	(69 k)	13.9 m	13.4 m	15.4 m	21.2 m	23 m	25.5 m	29.1 m	31.5 m	32.1 m
Accounts Payable	(1.5 m)	(1.7 m)	6.8 m	7.6 m	8.2 m	8.6 m	8.8 m	8.8 m	8.4 m	14.1 m	14.6 m